3-Pyridinecarboxamide, N-[2-(nitrooxy)ethyl]-/Nitorubin/Perisalol/2-(pyridine-3-carbonylamino)ethyl nitrate/2-[(Pyridin-3-ylcarbonyl)amino]ethylnitrat//NicorandilIkorel/SG-75/Dancor/Nikoran/Nicorandilum/2-[(Pyridin-3-ylcarbonyl)amino]ethyl nitrate/N-(2-hydroxyethyl)nicotinamide nitrate ester/2-[(3-Pyridinylcarbonyl)amino]ethyl nitrate/Adancor/N-[2-(nitroxy)ethyl]-3-pyridine carboxamide/Sigmart/2-Nicotinamidoethyl nitrate
456.7±25.0 °C at 760 mmHg
HS Code Reference
Personal Projective Equipment
For Reference Standard and R&D, Not for Human Use Directly.
provides coniferyl ferulate(CAS#:65141-46-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
The stable coronary artery disease (SCAD) population is a heterogeneous group of patients both for clinical presentations and for different underlying mechanisms. The recent European Society of Cardiology guidelines extensively review SCAD from its definition to patients’ diagnostic and therapeutic management. In this review, we deal with five topics that, in our opinion, represent the most intriguing, novel and/or clinically relevant aspects of this complex coronary condition. Firstly, we deal with a peculiar SCAD population: patients with angina and ‘normal’ coronary arteries. Secondly, we reinforce the clinical importance of a diagnostic approach based on the pretest probability of disease. Thirdly, we review and critically discuss the novel pharmacological therapies for SCAD patients. Finally, we analyse the results of the most recent clinical trials comparing revascularization versus optimal medical therapy in SCAD patients and review the currently recommended use of intracoronary functional evaluation of stenosis.
Stable Angina Pectoris
Marco Valgimigli 1, Simone Biscaglia
ATP-sensitive K+ channels; Cerebral artery; Nicorandil; Nitric oxide.
The Unique Action of Nicorandil on Cerebral Circulation
Hiroyuki Kinoshita 1 2, Shinji Kawahito 3, Kazumi Takaishi 4
Potassium channels and transporters maintain potassium homeostasis and play significant roles in several different biological actions via potassium ion regulation. In previous decades, the key revelations that potassium channels and transporters are involved in the production of gastric acid and the regulation of secretion in the stomach have been recognized. Drugs used to treat peptic ulceration are often potassium transporter inhibitors. It has also been reported that potassium channels are involved in ulcerative colitis. Direct toxicity to the intestines from nonsteroidal anti-inflammatory drugs has been associated with altered potassium channel activities. Several reports have indicated that the long-term use of the antianginal drug Nicorandil, an adenosine triphosphate-sensitive potassium channel opener, increases the chances of ulceration and perforation from the oral to anal regions throughout the gastrointestinal (GI) tract. Several of these drug features provide further insights into the role of potassium channels in the occurrence of ulceration in the GI tract. The purpose of this review is to investigate whether potassium channelopathies are involved in the mechanisms responsible for ulceration that occurs throughout the GI tract.
Gastrointestinal tract; H⁺/K⁺-ATPase; Potassium channels; Ulceration.
Potassium Channelopathies and Gastrointestinal Ulceration
Jaeyong Han 1, Seung Hun Lee 2, Gerhard Giebisch 1, Tong Wang 1
2016 Nov 15